Patient registries are now critical infrastructure, not nice-to-have evidence

What patient registries do in rare disease

A patient registry is an organised collection of data on patients with a specific condition, typically curated by a patient organisation, a clinical-society infrastructure, or a sponsor-supported registry organisation. In rare disease, registries are the principal source of natural-history evidence, real-world treatment-effect evidence, and patient-finding data.

The four operational uses that have moved registries into critical-infrastructure status:

• Regulatory submissions: natural-history data from registries supports single-arm trial designs and external comparators in conditions where randomised controlled trials are not feasible
• HTA decisions: registry-based real-world evidence is increasingly required as part of HTA submissions, particularly in markets with managed-access agreements
• Post-marketing commitments: post-approval registries are routinely required by regulators and HTA bodies as evidence-generation commitments
• Patient finding: registries are increasingly the channel through which trial-eligible patients are identified and through which approved therapies are matched to patients

Why the framing has shifted

Three forces have moved registries into critical-infrastructure status:

• The expanding orphan and ultra-rare pipeline has raised the demand for natural-history evidence beyond what conventional trial-design approaches can supply
• HTA bodies have raised the standard of evidence required for ultra-rare therapy decisions, and registry data is the practical source of that evidence
• The patient-finding model for ultra-rare conditions, particularly those with diagnostic odysseys, depends on registries as the connection point between diagnosis and care

The combined effect is that registries are now load-bearing for multiple steps in the rare-disease drug development and access lifecycle.

Why the funding model has not caught up

Most rare-disease registries are funded through a mix of:

• Patient organisation fundraising (variable, typically not sufficient for full operational funding)
• Sponsor support (typically tied to specific programs and specific commercial milestones)
• Public research grants (intermittent, with funding cycles that do not align with operational continuity needs)

The mix sustained registries as research projects but does not sustain them as critical infrastructure. Operational continuity, data-quality investment, regulatory-grade governance, and the IT infrastructure to support multi-sponsor and multi-jurisdiction use all require sustained funding that the current mix does not consistently provide.

What this means for the rare-disease ecosystem

For commercial teams, public-private partnership models for registry funding, federated-data infrastructure approaches, and registry consortia with governance structures that allow multi-sponsor access are emerging as the practical answers. The ecosystem is moving from "each sponsor builds or funds the registry it needs" toward "shared registry infrastructure that multiple stakeholders, including multiple sponsors, jointly fund and use."

For the public-policy frame, the question is whether rare-disease registries should be treated as health-system infrastructure (funded similarly to other diagnostic and care infrastructure) or as research infrastructure (funded through the existing grant-and-sponsor model). The treatment-decision will shape rare-disease care for the next decade.